Author(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical Background In ZUMA-1 (NCT02348216), axi-cel, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, demonstrated significant benefit in patients with refractory large B cell lymphoma with an objective response rate (ORR)...
Pro zobrazení tohoto obsahu je třeba být přihlášen.